Overview

A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia

Status:
NOT_YET_RECRUITING
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety of SEP-363856 (75 mg/day or 100 mg/day) administered for 52 weeks in adult participants with schizophrenia
Phase:
PHASE3
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Treatments:
SEP-363856